MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference
January 11, 2023 14:25 ET
|
MiNK Therapeutics
NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic,...
MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference
November 17, 2022 09:00 ET
|
MiNK Therapeutics
NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic,...
MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline
November 10, 2022 09:05 ET
|
MiNK Therapeutics
Allogeneic off-the-shelf iNKT cell therapy, agenT-797, alone and in combination with pembro/nivo reports early clinical activity in solid tumors, with 27% and 66% of patients, respectively, had a...
MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results
November 03, 2022 08:00 ET
|
MiNK Therapeutics
- Five presentations on clinical data and novel pipeline candidates at the Society of Cancer Immunotherapy (SITC) Meeting- R&D Day on November 10, 2022, from 4:00-6:00pm ET in Boston and via...
MiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update
October 20, 2022 09:00 ET
|
MiNK Therapeutics
NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic,...
MiNK Therapeutics to Host R&D Event November 10, 2022
October 05, 2022 09:16 ET
|
MiNK Therapeutics
Experts in disease pathways discuss clinical data of allo-iNKTsR&D strategy driving pipeline momentum, productivity, and innovationInternal scalable manufacturing of fully allogeneic iNKT cells;...
MiNK Selected for Five Presentations at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
October 05, 2022 08:30 ET
|
MiNK Therapeutics
Clinical data on AgenT-797, allogeneic (allo) iNKTs, +/- anti-PD-1 in advanced solid tumorsClinical data of AgenT-797 in viral ARDS and refractory multiple myelomaNew therapeutic candidates: 1)...
MiNK Therapeutics to Participate at Upcoming Investor Conferences
August 31, 2022 09:00 ET
|
MiNK Therapeutics
NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic,...
MiNK Therapeutics Reports Corporate Update and Second Quarter 2022 Financial Results
August 09, 2022 08:00 ET
|
MiNK Therapeutics
Novel stromal-CAR-iNKT shows activity in solid tumors; FIH planned for 2023Clinical presentation of AgenT-797 in solid tumors, myeloma, and ARDS planned for 2H2022Under the leadership team of Dr. Joy...
MiNK Therapeutics to Participate at BTIG Biotechnology Conference
August 02, 2022 08:30 ET
|
MiNK Therapeutics
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic,...